Source: Health Canada shortage reports · Updated Jul 30, 2026
Some Abacavir products are in shortage in Canada (1 of 3 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Sep 11, 2026.
Products affected
1 / 3
In shortage since
Jul 28, 2026
Est. full return
Sep 11, 2026
Reports on file
9
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · since Jul 28, 2026, est. end Sep 11, 2026 · Disruption of the manufacture of the drug.
Anticipated
MINT-ABACAVIR
300MG · TABLET · MINT PHARMACEUTICALS INC
DIN 02480956 · Disruption of the manufacture of the drug.
Resolved
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · ended Sep 26, 2024 · Disruption of the manufacture of the drug.
Discontinued
ZIAGEN
300MG · TABLET · VIIV HEALTHCARE ULC
DIN 02240357
Resolved
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · ended Aug 11, 2023 · Disruption of the manufacture of the drug.
Resolved
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · ended Aug 10, 2022 · Disruption of the manufacture of the drug.
Resolved
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · ended Jan 21, 2019 · Disruption of the manufacture of the drug.
Resolved
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · ended Jan 15, 2018 · Disruption of the manufacture of the drug.
Resolved
APO-ABACAVIR
300MG · TABLET · APOTEX INC
DIN 02396769 · ended Apr 27, 2017 · Disruption of the manufacture of the drug.
What's happening
Abacavir is currently affected by an active shortage report filed with Health Canada by APOTEX INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Abacavir is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AF).
Recent changes
Jul 30, 2026
New report filed
Jul 27, 2026
New report filed
Common questions
When will Abacavir be back in stock in Canada?
The latest manufacturer estimate is Sep 11, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Abacavir in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.